Cohort study of capecitabine plus oxaliplatin (XELOX) together with Bevacizumab as the first-line therapy in advance or recurrent colorectal cancer.
Phase 4
Recruiting
- Conditions
- Advance or recurrent colorectal cancer.
- Registration Number
- JPRN-UMIN000006057
- Lead Sponsor
- Tokyo Medical University The third department of surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Patient who fall under the a package insert "contraindication" or "Contraindicaton in combination" with Bevacizumab , Oxaliplatin and Capecitabine. (2) Not appropriate for the study at the physician's assessment
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method Response rate Response rate at the fourth course Time-to-treatment failure Overall survival Resection rate in subjects with liver metastasis R0 resection rate in subjects with liver metastasis Safety Assessment of Quality of life (Dermatology Life Quality Index)